InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. PatentsNewsfile Corp • 08/21/24
InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On TuesdayBenzinga • 08/20/24
InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's DiseaseNewsfile Corp • 08/20/24
InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study DataNewsfile Corp • 07/30/24
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateNewsfile Corp • 05/14/24
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory BoardNewsfile Corp • 04/18/24
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular DegenerationNewsfile Corp • 04/16/24
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease StudiesNewsfile Corp • 04/04/24
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business UpdateNewsfile Corp • 02/13/24
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial OfficerNewsfile Corp • 02/09/24
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ETNewsfile Corp • 01/18/24
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business UpdateNewsfile Corp • 11/14/23
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023Newsfile Corp • 11/02/23
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq RulesNewsfile Corp • 10/26/23
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq RulesNewsfile Corp • 10/24/23
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept StudiesNewsfile Corp • 10/24/23
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business UpdateNewsfile Corp • 09/29/23
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price ComplianceNewsfile Corp • 09/22/23